A roundtable discussion of aromatase inhibitors as therapy for breast cancer

D. Craig Allred, Michael Baum, Aman U. Buzdar, Robert W. Carlson, Mitchell Dowsett, Richard M. Elledge, William J. Gradishar, Generosa Grana, Anthony Howell, Eleftherios P. Mamounas

Research output: Contribution to journalArticle

7 Scopus citations


This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.

Original languageEnglish (US)
Pages (from-to)213-222
Number of pages10
JournalBreast Journal
Issue number3
Publication statusPublished - May 1 2003



  • Anastrozole
  • Aromatase inhibitor
  • Breast cancer
  • Estrogen receptor
  • Exemestane
  • Letrozole
  • Postmenopausal

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Cite this

Allred, D. C., Baum, M., Buzdar, A. U., Carlson, R. W., Dowsett, M., Elledge, R. M., ... Mamounas, E. P. (2003). A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast Journal, 9(3), 213-222. https://doi.org/10.1046/j.1524-4741.2003.09305.x